Journals / Androloji Bülteni / 2021 / Cilt: 23 - Sayı: 4

Polikistik over sendromunda androjen seviyeleri ve seksüel disfonksiyon

Pages
244–249
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

No correlation was found between total FSFI, desire, arousal, lubrication, orgasm, sexual satisfaction scores and androgen levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:OBJECTIVE: We aimed to examine sexual function and relationship between sexual function and androgen levels in polycystic ovary syndrome (PCOS).
📊
Key Findings & Data:MATERIAL and METHODS: Twenty-five patients diagnosed with PCOS and 25 age, gender-matched controls were enrolled into the study.
💡
Conclusion & Impact:No correlation was found between total FSFI, desire, arousal, lubrication, orgasm, sexual satisfaction scores and androgen levels.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

OBJECTIVE: We aimed to examine sexual function and relationship between sexual function and androgen levels in polycystic ovary syndrome (PCOS). MATERIAL and METHODS: Twenty-five patients diagnosed with PCOS and 25 age, gender-matched controls were enrolled into the study. Subjects were evaluated with female sexual function index (FSFI) and Beck Depression Inventory (BDI) questionnaires. Free testosterone, total testosterone, dehydroepiandrosterone sulfate (DHEA-SO4), androstenedione, prolactin, sex hormone binding globulin (SHBG), follicle-stimulating hormone (FSH), luteinizing hormone (LH) and estradiol levels were measured and free androgen index (FAI) was calculated. We compared between patients and control groups these values. RESULTS: Total FSFI score 26.17±4 was in the PCOS group whereas, healthy women had a total FSFI score of 28.61±4.68. FSD was diagnosed in 4 of 25 patients (% 16) while 5 of 25 (% 20) healthy women had FSD (p=0.57). There is no statistically significant difference between sexual desire (p=0.89), arousal (p=0.10), lubrication (p=0.057), orgasm (p=0.18) and satisfaction domain (p=0.78) scores. The sexual pain score (p=0.002) was found to be significantly lower in women with PCOS. BDI scores was significantly higher in PCOS women (p=0.002). No correlation was seen between androgen level and FAI and total FSFI score and domain score. CONCLUSION: Scores related to sexual desire, arousal, lubrication, satisfaction and orgasm disorders in PCOS patients are similar to those of control individuals, while scores for depression are higher than control individuals. No correlation was found between total FSFI, desire, arousal, lubrication, orgasm, sexual satisfaction scores and androgen levels.

Özet

AMAÇ: Poliskistik over sendromunda (PKOS) seksüel fonksiyonun sorgulanmasını ve seksüel fonksiyonun andojen seviyeleri ile ilişkisini saptamayı amaçladık. GEREÇ ve YÖNTEMLER: Yirmi beş PKOS tanılı hasta ve yaş, cins uyumlu 25 kontrol çalışmaya alındı. Kontrol ve hasta grubundaki bireylere Kadın Seksüel Fonksiyon İndeksi (FSFI) ve Beck Depresyon Anketi (BDA) yapıldı. Katılımcılardan serbest testosteron, total testosteron, dihidroepiandrostenodion sülfat (DHEA-S), androstenedion, prolaktin, seks hormon bağlayıcı globülin (SHBG), follikül uyaran hormon (FSH), luteinizan hormon (LH) ve östradiol ölçümleri için örnekler alındı. Serbest androjen indeksi (SAİ) hesaplanıldı. PKOS hasta grubu ve kontrol grubu arasında bu değerler karşılaştırıldı. BULGULAR: PKOS hasta grubunun total FSFI skoru 26,17±4 iken kontrol grubunun total FSFI skoru 28,61±4,68 saptandı. FSFI skorlamasına göre PKOS’lu kadınların %16’sında (n=4) sağlıklı kontrollerin %20’sinde (n=5) seksüel disfonksiyon tespit edildi (p=0,57). PKOS grubu ile kontrol grubu arasında seksüel istek (p=0,89), uyarılma (p=0,10), lubrikasyon (p=0,057), orgazm (p=0,18) ve tatmin (p=0,78) skorlamaları arasında fark olmadığı, seksüel ağrı skorlamasının (p=0,002) ise PKOS’lu kadınlarda anlamlı oranda düşük olduğu belirlendi. PKOS grubunda kontrol grubuna göre BDA skorlaması anlamlı oranda yüksek bulundu (p=0,002). Androjen seviyeleri ve SAİ ile total FSFI ve FSFI alt alanları arasında korelasyon saptanmadı. SONUÇ: Sonuç olarak, PKOS hastalarında seksüel istek, uyarılma, lubrikasyon, tatmin ve orgazm bozuklukları ile ilgili skorlar, kontrol bireylerdekine benzer, depresyon ile ilgili skorlar ise kontrol bireylere göre daha yüksek görülmektedir. Total FSFI, istek, uyarılma, lubrikasyon, orgazm, seksüel tatmin skorlamaları ile androjen seviyeleri arasında korelasyon tespit edilmemiştir.

🔖

Cite This Article

KADIOĞLU, P., EROL, R. S. (2022). Polikistik over sendromunda androjen seviyeleri ve seksüel disfonksiyon. Androloji Bülteni, Cilt: 23 - Sayı: 4, 244–249. https://ajindex.com/articles/439629

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet 2007 25;370:685–97. [CrossRef] 2. Azziz R. Polycystic Ovary Syndrome. Obstet Gynecol 2018;132:321–36. [CrossRef] 3. Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2004;60:1– 17. [CrossRef] 4. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19–25. [CrossRef] 5. Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, et al. The Polycystic Ovary Syndrome: an Endocrinological Perspective from the European Society of Endocrinology. Eur J Endocrinol 2014;171:P1–29. [CrossRef] 6. Vegunta S, Kling JM, Kapoor E. Androgen Therapy in Women. J Womens Health (Larchmt) 2020;29:57–64. [CrossRef] 7. Braunstein GD. Androgen insufficiency in women. Growth Horm IGF Res 2006;16:109–17. [CrossRef] 8. Cappelletti M, Wallen K. Increasing women’s sexual desire: The comparative effectiveness of estrogens and androgens. Horm Behav 2016;78:178–93. [CrossRef] 9. Buster JE, Kingsberg SA, Aguirre O, Brown C, Breaux JG, Buch A, et al. Testosterone patch for low sexual desire in surgically menopausal women: a randomized trial. Obstet Gynecol 2005;105:944–52. [CrossRef] 10. Guay AT. Decreased testosterone in regularly menstruating women with decreased libido: a clinical observation. J Sex Marital Ther 2001;27:513–9. [CrossRef] 11. Motta-Mena NV, Puts DA. Endocrinology of human female sexuality, mating, and reproductive behavior. Horm Behav 2017;91:19–35. [CrossRef] 12. Tuiten A, Van Honk J, Koppeschaar H, Bernaards C, Thijssen J, Verbaten R. Time course of effects of testosterone administration on sexual arousal in women. Arch Gen Psychiatry 2000;57:149–53;discussion 155–6. [CrossRef] 13. Thannickal A, Brutocao C, Alsawas M, Morrow A, Zailem F, Murad MH, et al. Eating, sleeping and sexual function disorders in women with polycystic ovary syndrome (PCOS): A systematic review and meta-analysis. Clin Endocrinol (Oxf) 2020;92:338– 49. [CrossRef] 14. Bhasin S, Enzlin P, Coviello A, Basson R. Sexual dysfunction in men and women with endocrine disorders. Lancet 2007 17;369:597–611. [CrossRef] 15. Janssen OE, Hahn S, Tan S, Benson S, Elsenbruch S. Mood and sexual function in polycystic ovary syndrome. Semin Reprod Med 2008;26:45–52. [CrossRef] 16. Rosen R, Brown C, Heiman J, L